106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ACRJIAO02223a
Source
Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatolog y
Guideline for the Treatment of Juvenile Idiopathic Arthritis: erapeutic Approaches
for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic
Arthritis, Arthritis & Rheumatolog y, 2022 Mar 2. doi: 10.1002/art.42037. Epub ahead
of print.
Abbreviations
DMARD, disease-modifying antirheumatic drug ; GC, glucocorticoid; HCQ,
hydroxychloroquine; IAGCs, intra-articular glucocorticoids; IL, interleukin; JAK, janus
kinase; JIA, juvenile idiopathic arthritis; LEF, leflunomide; MAS, macrophage activation
syndrome; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; OBRM,
other biologic response modifiers; SSZ, sulfasalazine; THA, triamcinolone hexacetonid;
TMJ, temporomandibular joint; TNFi, tumor necrosis factor alpha inhibitors
Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality
patient care. It is applicable to specialists, primary care, and providers at all levels. is
pocket guide should not be considered exclusive of other methods of care reasonably directed at
obtaining the same results. e ultimate judgment concerning the propriety of any course of
conduct must be made by the clinician aer consideration of each individual patient situation.
Neither IGC, the American College of Rheumatology, nor the authors endorse any product or
service associated with the distributor of this clinical reference tool.
